The ideal therapeutic approach for lupus nephritis (LN) is to quickly achieve a complete remission and maintain that response long-term while minimizing drug toxicity, and prevent tissue damage and death. The combination therapy consisting of multiple medications is aimed at incorporating drugs with complementary actions at reduced doses to achieve additive or synergistic therapeutic effects while minimizing toxicity. Here, we review the available evidence using combination therapies (triple therapy) and how such strategies can improve therapeutic efficacy in LN, which will mainly focus on the combination of high-dose corticosteroids with mycophenolate mofetil (MMF) and a calcineurin inhibitor (CNI) at low dose. We discuss the rationale, efficacy, and safety of the therapy, as well as its molecular mechanisms. We also discuss the questions raised from the trials and briefly describe emerging approaches developed on the basis of combination therapy, and these advances that promise to improve on the standard-of-care treatments and toward individual therapy in LN.

Rationale of Combination Therapy
SLE is an autoimmune disease that affects multiple organs and tissues. Renal involvement is the most important predictor of morbidity and mortality. The immune dysregulation is fundamental to the pathogenesis of LN, with B cells, T cells, and complement activation involved in the development of the disease. Current widely accepted treatment regimens for LN incorporate high-dose corticosteroids for rapid control of inflammation and immunosuppression to control inflammation and autoimmunity. However, the incidence of complete remission with these regimens remains low, and adverse events are still a major concern. Therefore, new therapeutic approaches for LN are needed.

MMF is known to be a selective lymphocyte anti-proliferative agent and reversibly inhibits the de novo pathway of purine synthesis in the proliferation of B and T lymphocytes. The Aspreva Lupus Management Study firmly established the use of MMF as an alternative initial treatment for LN. Corticosteroids combined with MMF is one of the current standard-of-care induction treatment regimens for active severe LN. CNIs block T-cell activation through suppressing the calcium and calcimodulin-dependent phosphatase calcineurin. They are attractive therapeutic options for LN. Their effects attributed both to their immunosuppressive efficacy and the action of these agents on podocyte biology leading to more rapid proteinuria suppression and a higher complete response rate.
Tacrolimus (TAC) is a potent CNI used for prevention of rejection in organ transplant recipients.15–17 Results from a randomized clinical trial, which compared TAC against intravenous cyclophosphamide (IVCY) in active proliferative LN, showed comparable efficacy of TAC (complete response rates were 52.4% in the TAC group and 38.5% in the IVCY group).18 Combination therapy consisting of multiple medications is aimed at incorporating drugs with complementary actions at reduced doses to achieve additive or synergistic therapeutic effects while minimizing toxicity. In fact, combination therapy with steroids, TAC, and MMF has been used for many years as an antirejection therapy in transplant patients.15–17

We conducted a pilot study to evaluate the combination therapy of high-dose steroids with MMF and TAC at low dose in patients with concurrent class IV and V LN, which constitutes an important fraction of severe LN and is often refractory to conventional treatment.19 The combination therapy demonstrated a higher incidence of complete remission and overall response in patients with LN with significant membranous features in the kidney biopsy compared with IVCY and steroids. In addition, the combination therapy group experienced fewer adverse events than the IVCY group.19

Efficacy and Safety of Combination Therapy
To further assess the efficacy and safety of the combination therapy, a prospective, multicenter, randomized controlled trial was conducted in China.20 A total of 368 patients with biopsy-proven LN with class III, IV, V, III+V, and IV+V lesions were randomly assigned to the combination regimen or IVCY group. Both groups received i.v. methylprednisolone pulse therapy (0.5 g/d) for 3 days, followed by oral prednisone. The combination group received TAC (2 mg twice daily) and MMF (0.5 g twice daily), whereas the IVCY group received an initiating dose of 0.75 (adjusted to 0.5 to 1.0) g/m² of body surface area every 4 weeks. After 6 months of therapy, significantly more patients in the combination group than in the IVCY group achieved complete remission (45.9% vs. 25.6%, P < 0.001). The cumulative probability of complete remission was also higher in the combination group than the IVCY group (45.8% vs. 26.8%, P < 0.001). The overall response incidence was significantly higher in the combination group compared with the IVCY group (83.5% vs. 63.0%, P < 0.001). Noteworthy, the combination therapy is associated with more rapid proteinuria reduction and thus a higher early response rate. The median time to overall response was shorter (8.9 weeks vs. 13.0 weeks) in the combination group. In addition to markedly decreased proteinuria, the combination group also accompanied with significant changes in SLE–disease activity index score and serum C3 levels at the same time.20 These observations, together with the finding of transcriptional profile of renal biopsy tissue from patients with LN and in a mouse model of lupus-like nephritis, which will be introduced later on, implicate that the immune mechanism of the combination therapy plays a role in treatment of LN.21

The disease manifestations and outcomes in LN are heterogeneous, and renal histopathology findings have an important role in informing treatment decisions and prognosis prediction. Subgroup analysis was performed according to the pathologic classification. It was shown that the incidence of complete remission rate was higher in the combination group than the IVCY group among patients with class IV LN (51.5% vs. 29.9%), class V LN (33.1% vs. 7.8%), and class IV + V LN (45.2% vs. 26.5%).22 These findings suggested that combination therapy may be a valuable treatment approach in patients with LN not only with proliferative lesions (class IV) but with membranous (class V) lesions that usually do not respond well to conventional treatment. Patients with class V (with or without concurrent class IV or III) may need to consider choosing the combination therapy as an alternative therapy, including young women to avoid ovarian toxicity from cyclophosphamide therapy. The combination therapy needs to be used cautiously in patients to avoid nephrotoxicity and metabolic side effects of CNI.

To observe resolution of renal tissue injury after treatment, repeat renal biopsies were done in some patients after treatment. It was revealed that glomerular mesangial and subendothelial immune deposits were significantly reduced, the “wire loops” and thrombi disappeared with remaining mild to moderate mesangial expansion and occasional endothelial cell proliferation. The intensity of staining for glomerular IgG deposition also decreased. Although the activity index markedly decreased in both treatment groups, with numerically more pronounced changes in the combination group (Figure 1). These observations indicated that clinical remission accompanied histologic remission in the kidney tissue after the treatment.

Most patients in the combination group tolerate the therapy well, with a similar incidence of adverse events (50.3% vs. 52.5%) to IVCY during the induction phase.20 Compared with IVCY, the combination therapy was less likely to cause ovarian failure, as well as gastrointestinal symptoms, leukopenia, and liver dysfunction.20,22 However, despite no statistical significance, the incidence of serious adverse events was numerically higher in the combination group (7.2% vs. 2.8%), mostly due to infection, including pneumonia, varicella zoster virus, and upper respiratory tract
infection. The adverse events should be monitored cautiously during treatment. Therapeutic drug monitoring is a useful tool to minimize drug-related toxicities. In this trial, the mean blood trough concentration of TAC was approximately 5.5 ng/ml and mycophenolic acid area under the concentration-versus-time curve was approximately 30 mg.h/l during the induction phase. The target blood trough concentrations of TAC were 5 to 10 ng/ml according to the protocol. The dosage of TAC was reduced in those who had a blood concentration that continued to be >10 ng/ml, with or without signs of toxicity or changes of serum creatinine. Mycophenolic acid area under the concentration-versus-time curve between 35 and 45 mg.h/l was suggested during initial therapy. In those who had obvious gastrointestinal symptoms or leukopenia, the dosage of MMF was reduced. Because the pharmacokinetics of TAC and mycophenolic acid has a high interindividual variability, the blood levels should be carefully monitored and adjusted during treatment.

To assess the efficacy and safety of combination therapy for maintenance treatment in LN, we continued to treat patients for an additional 18 months and compared them with those of azathioprine (AZA) treatment in 206 patients with LN. Patients who achieved a complete or partial remission in the induction trial were recruited for an additional 18 months of treatment. The combination group continued to receive reduced doses of TAC (2–3 mg/d) and MMF (0.5–0.75 mg/d), whereas the IVCY group was switched to AZA (2 mg/kg body weight per day). Oral prednisone was administered to all participants at a dosage of 10 mg/d. There were no significant differences in cumulative renal relapse rates (5.47% vs. 7.62%, P = 0.74) between groups. The adverse events were significantly higher in the AZA group, and the combination group had a lower withdrawal rate. The percentages of patients in the combination therapy group who maintained their complete remission status at 12 and 18 months were 72.5% and 78.3%, respectively, and the corresponding percentages in the AZA group were 67.6% and 78.0%; the differences were not significant between the 2 groups. Accumulated evidence suggests that earlier achievement of remission is associated with a better long-term outcome, patients with early remission spent significantly less of their follow-up time with active disease, had lower annual relapse rates, and lower cumulative steroid dosage, lower average scores for disease activity (SLE–disease activity index) than those with persistent activity. As we discussed previously, the complete remission observed in the combination group not only showed decreased proteinuria, but also was accompanied with significant changes in SLE–disease activity index score and serum C3 levels. Repeat renal biopsy revealed a solution of immune injury in kidney tissue. This evidence indicated that combination therapy preserved the kidney from active tissue injury much more rapidly and effectively than IVCY. In addition, combination therapy was associated with a decreased incidence of
adverse events compared with AZA, especially in leukopenia and liver dysfunction. This may be related to the lower dosages required during the maintenance phase. Therefore, combination therapy is more effective than IVCY, and long-term and extended studies are needed to evaluate the advantage of combination therapy in LN. In addition, we may need to consider using combination therapy for induction therapy in active LN to quickly achieve a complete remission, and then sequentially switch to the regimen of standard-of-care treatment for maintenance therapy.

The approach of this kind of combination therapy was tested in subsequent clinical trials. Meta-analysis showed that the combination therapy is more effective for inducing remission compared with IV CY, MMF, and CNIs. Besides initial treatment, it can also help refractory or relapsing patients achieve a renal response and reduce the use of steroids. Not only tacrolimus but also cyclosporine combined with MMF can induce complete remission in LN and was well tolerated. Recently, the addition of low-dose voclosporin, a new CNI, showed a superior renal response compared with background MMF and corticosteroids alone in the Aurinia Urinary Protein Reduction Active-Lupus With Voclosporin trial. The complete renal remission rate was significantly higher with low-dose voclosporin than with placebo at week 24 (32.6% vs. 19.3%) and week 48 (49.4% vs. 23.9%). Complete renal remission was achieved more rapidly in the voclosporin plus MMF group than in the MMF-alone group. Importantly, it also demonstrated the efficacy of the combination therapy in a global cohort, suggesting that such combination therapy may be applicable to multi-ethnic patients with LN. In the Aurinia Urinary Protein Reduction Active-Lupus With Voclosporin study, however, there were more serious adverse events, including deaths, in the combination therapy group. The incidence of adverse events was disproportionately higher in low-dose voclosporin group even when compared with the high-dose group, suggesting mortality may not be directly linked to drug exposure but rather to other factors, which is expected to be addressed in future studies.

Other triple regiments included various drug combinations of corticosteroids, CNIs, cyclophosphamide, or mizoribine. Observational studies, most of which were performed in Japan, reported short-term efficacy of these regimens. But the results were limited by small sample size, insufficient observation period, and absence of controls.

Recently, several novel approaches to treatment that have more specific effects on the immune system have been studied in LN. B cells play an important role in the pathogenesis of LN and are therefore attractive therapeutic targets. B-cell depletion by rituximab results in enhanced expression of B lymphocyte-stimulator, also known as B-cell–activating factor. The B lymphocyte-stimulator stimulates B-cell reconstitution and may facilitate development of autoreactive B cells, negating the effect of anti-CD20 therapy. Using belimumab (a humanized monoclonal antibody inhibitor of soluble B-cell–activating factor) may theoretically decrease relapses induced by higher B-cell–activating factor levels post-rituximab. Recently, reports illustrated a promising value of adding belimumab after rituximab treatment in LN. The Immune Tolerance Network CALIBRATE study will further test this hypothesis by sequential administration of cyclophosphamide plus rituximab followed by belimumab in a multicenter randomized clinical trial (identifier: NCT02260934).

Molecular Basis of Combination Therapy

To explore the underlying molecular and cellular mechanisms of increased efficacy of the combination therapy regimen, especially to reveal whether there are any additive or synergistic effects from this kind of combination, we used a mouse model of LN, MRL/lpr mice, and treated them with monotherapies of prednisone, MMF, or tacrolimus, or with their combination. Transcriptome profile of kidney tissue from the combination therapy group was most similar to that of the healthy control, indicating that the combination therapy effectively restored the expression of genes altered in the LN kidney to a normal phenotype. Pathway enrichment analysis revealed that several key molecules or pathways involved in LN were regulated uniquely in the combination therapy group. Compared with monotherapies, the top downregulated differentially expressed genes were involved in both T- and B-cell receptors and in type II interferon signaling pathways in the combination group. In addition, the study demonstrated that the combination therapy led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities. The beneficial effects of the combination therapy may be due to the additive influence on immune or nonimmune pathways in the kidney.

Interestingly, the combination group showed enhanced suppression in the activity of toll-like receptor (TLR) 7 and the expression of interleukin (IL)-6/Stat3 pathway, which are known to be deeply involved in the pathogenesis of LN. These findings were further validated in renal biopsy samples from patients with LN before and after treatments with MMF, TAC, or combination therapy. Plenty of data implied an important role for TLR7 in both...
murine and human SLE and LN. Unregulated TLR7 induces distinct effector B cells and contributes to pathogenic responses in lupus.46 Enhanced responsiveness to TLR7 may adversely affect B-cell tolerance even at the early transitional stage and facilitate expansion of autoreactive B cells.47,48 Pharmacological TLR7 activation stimulates a B-cell–and dendritic cell–dependent systemic immune response and aggravates LN.49,50 IL-6 is a pleiotropic cytokine with a wide range of biological activities in immune regulation and inflammation.51 IL-6 levels are elevated in both human and murine lupus and blocking IL-6 or its receptor had a beneficial effect in models of lupus.52 However, phase II clinical trials of anti–IL-6 monoclonal antibody failed to demonstrate an anticipated efficacy in patients with SLE or LN.53,54 Because many components of the immune system are simultaneously involved in the generation of systemic and renal autoimmunity in LN, it may be insufficient to intervene in a single pathway to treat LN. In our validation study in patients with LN, circulating levels of IL-6 were significantly suppressed in patients who had shown complete remission response to combination therapy, when compared with those who had not.21 Whether serum IL-6 level could serve as an informative biomarker for treatment choice and a disease activity monitor in patients with LN may need to be determined in further study.

Conclusion
LN is an aggressive inflammatory disease; the ideal therapeutic approach is to quickly achieve a complete remission and maintain that response long-term while minimizing drug toxicity. Knowledge of pathogenesis of LN is growing quickly, and such new advances need to be translated into clinical practice. Combination therapy consisting of multiple medications is aimed at incorporating drugs with complementary actions at reduced doses to achieve additive or synergistic therapeutic effects while minimizing toxicity; such an approach could ideally be used to tailor treatment to the underlying molecular pathways. Combination therapies based on current and novel immunosuppressive and biological agents might hold particular promise for the development of innovative and highly individual therapies for LN.

DISCLOSURE
All the authors declared no competing interests.

REFERENCES
1. Shao SJ, Hou JH, Xie GT, et al. Improvement of outcomes in patients with lupus nephritis: management evolution in Chinese patients from 1994 to 2010. J Rheumatol. 2019;46:912–919.
2. Jorge A, Wallace ZS, Zhang Y, et al. All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol. 2019;71:403–410.
3. Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis. J Am Soc Nephrol. 2016;27:2929–2939.
4. Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68:1432–1441.
5. Wang Z, Wang Y, Zhu R, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systematic review of observational studies. Medicine (Baltimore). 2015;94:e794.
6. Wu XY, Yang M, Xie YS, et al. Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort. Clin Rheumatol. 2019;38:107–115.
7. Menez SP, El Essawy B, Atta MG. Lupus nephritis: current treatment paradigm and unmet needs. Rev Recent Clin Trials. 2018;13:105–113.
8. Yu F, Haas M, Glassock R, et al. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483–485.
9. Mak A, Isenberg DA, Lau CS. Global trends, potential mechanisms and early detection of organ damage in SLE. Nat Rev Rheumatol. 2013;9:301–310.
10. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioepine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet. 2004;364:503–512.
11. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–1112.
12. Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016;31:904–913.
13. Rovin BH, Caster DJ, Catran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95:281–295.
14. Mok CC. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:429–438.
15. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–2575.
16. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant. 2010;25:2004–2010.
17. Ekberg H, van Gelder T, Kaplan B, et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation. 2011;92:82–87.
18. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57:235–244.
19. Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V–IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001–2010.

20. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162:18–26.

21. Fu J, Wang Z, Lee K, et al. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney Int. 2018;93:416–429.

22. Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis. 2017;70:324–336.

23. van Gelder T, Berden JH, Berger SP. To TDM or not to TDM in lupus nephritis patients treated with MMF? Nephrol Dial Transplant. 2015;30:560–564.

24. Zhang H, Liu Z, Zhou M, et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol. 2017;28:3671–3678.

25. Gatto M, Zen M, Iaccarino L, et al. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15:30–48.

26. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010;19:949–956.

27. Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1–8.

28. Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27:1007–1011.

29. Almutairi A, Alkathiri Z, Al-Mayouf SM. Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis. Int J Pediatr Adolesc Med. 2018;5:99–102.

30. Jesus D, Rodrigues M, da Silva JAP, et al. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus. 2018;27:1358–1362.

31. Mao Y, Yin L, Huang H, et al. Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res. 2019;47:105–113.

32. Tang KT, Tseng CH, Hsieh TY, et al. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis. Int J Rheum Dis. 2018;21:1163–1172.

33. Deng J, Luo L, Zhu L, et al. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials. Turk J Med Sci. 2018;48:901–910.

34. Rovin BH, Solomons N, Pendergraft WF 3rd, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95:219–231.

35. Sin FE, Isenberg D. An evaluation of voclosporin for the treatment of lupus nephritis. Expert Opin Pharmacother. 2018;19:1613–1621.

36. Tanaka H, Aizawa T, Watanabe S, et al. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus. 2014;23:813–818.

37. Sakai R, Kurasawa T, Nishi E, et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus. 2018;27:273–282.

38. Kagawa H, Hiromasa T, Yamanaka R, et al. The first year results of mizoribine/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis. Clin Exp Nephrol. 2018;22:1371–1378.

39. Ayoub I, Nelson J, Rovin BH. Induction therapy for lupus nephritis: the highlights. Curr Rheumatol Rep. 2018;20:60.

40. Krajj T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford). 2014;53:2122–2124.

41. Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G. Rituximab-refractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol. 2016;34:355–356.

42. Simonetta F, Allali D, Roux-Lombard P, et al. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2017;84:235–236.

43. Psarelis S, Nikiphorou E, Boumpas DT. Successful use of sequential B-cell depletion therapy in lupus. Lupus. 2018;27:345–346.

44. Fontana F, Alfano G, Leonelli M, et al. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report. BMC Nephrol. 2018;19:276.

45. Krajj T, Kamerling SWA, de Rooij EMM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45–54.

46. Jenks SA, Cashman KS, Zumaquero E, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49:725–739.e6.

47. Giltiy NV, Chappell CP, Sun X, et al. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. J Exp Med. 2013;210:2773–2789.

48. Kolhatkar NS, Brahmandam A, Thouvenel CD, et al. Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome. J Exp Med. 2015;212:1663–1677.

49. Pawar RD, Patole PS, Zecher D, et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol. 2006;17:141–149.

50. Lorenz G, Lech M, Anders HJ. Toll-like receptor activation in the pathogenesis of lupus nephritis. Clin Immunol. 2017;185:86–94.
51. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. *Arthritis Res*. 2002;4(Suppl 3):S233–S242.

52. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. *Lupus*. 2004;13:339–343.

53. Rovin BH, van Vollenhoven RF, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. *Arthritis Rheumatol*. 2016;68:2174–2183.

54. Wallace DJ, Strand V, Merrill JT, et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. *Ann Rheum Dis*. 2017;76:534–542.